Genetic Counseling Market Size, Share & Industry Analysis, By Service Type (Pre-test Counseling, Post-test Counseling, Integrated Counseling, and Follow-up & Family Counseling, and Others), By Application (Reproductive Genetics, Oncology Genetics, Pediatric & Rare Disease Genetics, Cardiovascular & Neurogenetics, Predictive & Pharmacogenomic Genetics, and Others), By Age Group (Adults and Pediatric), By End User (Hospitals & Academic Centers, Genetic Counseling Clinics, and Others), and Regional Forecast, 2026-2034

The global genetic counseling market size was valued at USD 1.46 billion in 2025. The market is projected to grow from USD 1.58 billion in 2026 to USD 2.89 billion by 2034, exhibiting a CAGR of 7.9% during the forecast period.

The global market comprises professional services that help individuals and families understand the medical, psychological, and familial implications of inherited or potentially inherited conditions. Services include pre-test risk assessment, informed-consent support, post-test interpretation, integrated counseling throughout the diagnostic or treatment pathway, and follow-up counseling for patients and relatives. The market growth is attributed to expanding genetic testing availability, increasing use of hereditary cancer and reproductive screening, growing diagnosis of rare diseases, rising adoption of precision medicine, and wider use of telehealth-enabled genetics services.

• For instance, in June 2025, Genome Medical announced delivery of its 250,000th genetic counseling session, reflecting increasing utilization of technology-enabled genetics services and growing demand for access to genetics expertise.

Genome Medical, Myriad Genetics, Inc., Natera, Inc., Labcorp, and GeneDx Holdings Corp. are among the prominent participants in the broader genetic counseling and clinical genomics ecosystem. Market participants are strengthening service accessibility through digital delivery, laboratory-integrated counseling, oncology and reproductive genetics programs, rare-disease expertise, and partnerships with healthcare providers.

GENETIC COUNSELING MARKET TRENDS

Increasing Adoption of Tele-genetic Counseling and Digitally Integrated Genomic Care are Transforming Service Delivery

Genetic counseling is increasingly moving beyond exclusively in-person consultations toward telehealth, hybrid care, digital intake, automated family-history collection, clinical decision support, and integrated test-ordering workflows. These models can extend access to genetics expertise in regions with limited counselor availability while allowing laboratories and health systems to embed counseling into oncology, reproductive health, pediatrics, and rare-disease pathways. Digital platforms are also supporting longitudinal engagement before testing, during result interpretation, and after diagnosis. The integration of artificial intelligence and workflow automation is expected to assist counselors with administrative and information-processing tasks while maintaining clinician-led interpretation and patient communication.

• For instance, in January 2025, Genome Medical and Nest Genomics partnered to integrate genetic counseling, genetic test ordering, medical consultations, and clinical decision support into scalable genomic-care workflows.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Expanding Genetic Testing and Personalized Medicine Adoption to Drive Market Growth

The increasing use of hereditary cancer panels, carrier screening, prenatal testing, exome and genome sequencing, pharmacogenomics, and predictive genetic testing is actively driving the global genetic counseling market growth. Genetic counselors help patients understand testing options, limitations, potential outcomes, family implications, and subsequent clinical actions. As genomic information becomes more integrated into oncology, reproductive medicine, pediatrics, cardiology, neurology, and preventive care, counseling is increasingly required across multiple stages of the patient journey. Growing awareness of inherited disease and the expansion of personalized medicine initiatives are therefore supporting sustained demand for genetic counseling services.

MARKET RESTRAINTS

Shortage of Trained Genetic Counselors and Uneven Reimbursement May Restrict Service Expansion

The availability of trained genetic counselors remains uneven across healthcare systems and geographies, creating appointment delays and limiting access outside major academic and urban centers. Reimbursement policies for genetic counseling also vary by payer, country, provider type, and delivery model, which can restrict standalone service economics. In addition, the rapid expansion of genetic testing is increasing case complexity and workload. At the same time, some healthcare systems rely on physicians, nurses, laboratory personnel, or digital tools for portions of the counseling pathway. These factors may constrain the pace at which specialist counseling capacity expands relative to genetic testing volumes.

MARKET OPPORTUNITIES

Integration of Counseling into Oncology, Rare Disease, and Population Genomics to Create Significant Opportunities

The expansion of genomic medicine creates opportunities to integrate genetic counseling directly into high-growth clinical pathways rather than treating it as a separate referral service. Oncology programs increasingly use germline testing to identify hereditary cancer risk and guide family testing, while pediatric and rare-disease programs use exome and genome sequencing to shorten diagnostic journeys. Population screening, pharmacogenomics, cardiovascular genetics, and preventive genomics could further broaden the addressable population. Scalable tele-genetics, laboratory partnerships, AI-supported workflows, and embedded counseling models can help providers expand access while preserving specialist oversight for complex cases.

MARKET CHALLENGES

Managing Increasing Genomic Complexity While Maintaining Patient-centered Communication Remains Challenging

Genetic counselors must translate increasingly complex genomic findings into understandable and clinically meaningful information while addressing uncertainty, incidental findings, and variants of uncertain significance, family implications, consent, privacy, and psychosocial concerns. Broader sequencing technologies can generate information beyond the original clinical question, increasing the need for careful communication and follow-up. The challenge is particularly significant in pediatric and rare-disease cases, where results may affect multiple relatives and reproductive decisions. Providers must therefore balance workflow scalability and digital automation with individualized counseling, ethical practice, and culturally appropriate communication.

Segmentation Analysis

By Service Type

Growing Need for Informed Testing Decisions Boosted Pre-test Counseling Segment

Based on service type, the market is divided into pre-test counseling, post-test counseling, integrated counseling, follow-up & family counseling, and others.

The pre-test counseling segment accounted for the largest global genetic counseling market share in 2025. The segment growth is attributed to increasing utilization of genetic testing across reproductive health, oncology, rare diseases, and preventive care, coupled with the need to evaluate family history, establish testing objectives, explain potential outcomes, and support informed consent before testing. Pre-test consultations help determine whether genetic testing is clinically appropriate, identify the most suitable test or panel, and prepare patients for positive, negative, uncertain, or incidental findings. Rising test availability and broader eligibility criteria are therefore supporting the segment's dominant share.

The integrated counseling segment is anticipated to rise with a CAGR of 9.4% over the forecast period.  

To know how our report can help streamline your business, Speak to Analyst

By Application

Rising Hereditary Cancer Testing Led to Dominance of Oncology Genetics Segment

Based on application, the market is segmented into reproductive genetics, oncology genetics, pediatric & rare disease genetics, cardiovascular & neurogenetics, predictive & pharmacogenomic genetics, and others.

The oncology genetics segment held the highest share of the global market in 2025. The segment growth is attributed to increasing hereditary cancer testing, broader use of multigene panels, growing awareness of BRCA and other cancer-predisposition genes, and greater integration of germline testing into oncology care. Genetic counseling supports cancer-risk assessment, test selection, interpretation of pathogenic variants and uncertain findings, cascade testing of relatives, and discussion of surveillance or risk-reduction options. Expanding precision-oncology programs and guideline-driven genetic testing are further strengthening demand.

The pediatric & rare disease genetics segment is anticipated to rise with a CAGR of 8.5% over the forecast period.  

By Age Group

Higher Testing Utilization Across Multiple Clinical Applications Propelled Adults Segment

Based on age group, the market is segmented into adults and pediatric.

The adults segment accounted for the largest share of the global market in 2025. The segment growth is attributed to the broad utilization of genetic counseling across hereditary cancer, reproductive planning, carrier screening, cardiovascular genetics, neurogenetics, predictive testing, and pharmacogenomics. Adults may seek counseling after a personal diagnosis and family history, reproductive considerations, or preventive risk assessment. The increasing availability of multigene panels and consumer awareness of inherited disease risk are further expanding counseling demand among adult populations.

The pediatric segment is anticipated to rise with a CAGR of 8.4% over the forecast period.

By End User

Concentration of Complex Genetic Care Led to Dominance of Hospitals & Academic Centers Segment

Based on end user, the market is segmented into hospitals & academic centers, genetic counseling clinics, and others.

The hospitals & academic centers segment held a 67.5% share in 2025. The segment growth is attributed to the concentration of oncology, maternal-fetal medicine, pediatrics, rare-disease programs, cardiovascular genetics, neurology, and advanced genomic testing within tertiary and academic healthcare systems. These institutions frequently maintain multidisciplinary genetics teams and provide access to specialist physicians, molecular laboratories, clinical trials, and complex diagnostic services. Integration of genetic counselors into disease-specific clinics further supports coordinated test selection, interpretation, family management, and long-term care.

The genetic counseling clinics segment is anticipated to rise with a CAGR of 9.3% over the forecast period.

Genetic Counseling Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024, valued at USD 0.59 billion, and also maintained the leading share in 2025, with USD 0.65 billion. The region benefits from high utilization of genetic testing, established oncology and reproductive genetics programs, broad adoption of telehealth, strong clinical genomics infrastructure, and the presence of specialized genetic counseling providers and major diagnostic laboratories.

U.S. Genetic Counseling Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 0.64 billion in 2026, accounting for roughly 40.9% of global sales.

Europe

Europe is projected to record a growth rate of 6.7% in the coming years and reach a valuation of USD 0.40 billion by 2026. Europe is expected to maintain a significant position during the forecast period, supported by established clinical genetics services, national and regional genomic medicine initiatives, rare-disease programs, cancer genetics, and expanding sequencing capacity.

U.K. Genetic Counseling Market

The U.K. market is estimated at around USD 0.06 billion in 2026, representing roughly 4.1% of global revenues.

Germany Genetic Counseling Market

Germany’s market is projected to reach approximately USD 0.07 billion in 2026, equivalent to around 4.6% of global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 0.34 billion in 2026 and secure a significant position in the market. The market is growing due to rising genetic disorder prevalence, expanding prenatal and cancer screening, declining sequencing costs, improving diagnostics, precision-medicine adoption, and increasing awareness of preventive genetic healthcare.

Japan Genetic Counseling Market

The Japanese market is estimated at around USD 0.07 billion in 2026, accounting for roughly 4.5% of global revenues.

China Genetic Counseling Market

China’s market is projected to be one of the largest globally, with 2026 revenues estimated at around USD 0.10 billion, representing roughly 6.1% of global sales.

India Genetic Counseling Market

The Indian market is estimated at around USD 0.05 billion in 2026, accounting for roughly 3.2% of global revenues.

Latin America and Middle East & Africa

Latin America and Middle East & Africa regions are expected to witness moderate growth in this market during the forecast period. The Latin American market is set to reach a valuation of USD 0.07 billion in 2026.  Latin America is growing through expanding prenatal and oncology testing, improving diagnostics, and precision-medicine adoption, while Middle East & Africa’s growth is driven by inherited-disease burden, premarital/prenatal screening, healthcare investment, and improving genetic-testing access.

GCC Genetic Counseling Market

The GCC market is set to reach a value of USD 0.03 billion in 2026.

South Africa Genetic Counseling Market

The South African market is projected to reach around USD 0.01 billion in 2026, representing roughly 0.7% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Portfolio Expansion and High-resolution Molecular Typing Capabilities Strengthen Market Positioning of Leading Players

The global genetic counseling market has a fragmented and evolving competitive structure comprising specialist counseling providers, genetic testing laboratories, genomics companies, and digital-health platforms. Prominent participants include Genome Medical, Myriad Genetics, Inc., Natera, Inc., Labcorp, and GeneDx Holdings Corp. These companies participate in the market through tele-genetic services, hereditary disease testing, reproductive genetics, oncology, rare-disease diagnostics, patient education, and laboratory-integrated counseling pathways.

• For instance, in June 2026, PreventionGenetics announced a partnership with Genome Medical to provide U.S. patients receiving genetic test results with access to post-test counseling delivered by licensed, board-certified genetic counselors.

Other notable participants include Color Health, Inc., MedGenome, Fulgent Genetics, Inc., BGI Genomics Co., Ltd., and DNAFeed Inc. Market participants are expected to focus on telehealth expansion, integrated testing-and-counseling pathways, AI-supported workflows, oncology and rare-disease specialization, and partnerships with health systems and diagnostic laboratories.

LIST OF KEY GENETIC COUNSELING COMPANIES PROFILED

• Genome Medical (U.S.)
• Myriad Genetics, Inc. (U.S.)
• Natera, Inc. (U.S.)
• Labcorp (U.S.)
• GeneDx Holdings Corp. (U.S.)
• Color Health, Inc. (U.S.)
• MedGenome (India)
• Fulgent Genetics, Inc. (U.S.)
• BGI Genomics Co., Ltd. (China)
• DNAFeed Inc. (Canada)

KEY INDUSTRY DEVELOPMENTS

• December 2025: Zydus Lifesciences signed an exclusive agreement with Myriad Genetics to introduce the MyRisk Hereditary Cancer Test, MyChoice HRD Plus, and Prolaris Prostate Cancer Prognostic Test in India, expanding access to hereditary cancer risk assessment and precision-oncology
• June 2025: Novo Genomics and Avigena signed a strategic partnership to provide genomic testing and personalized health services for Arab populations across Saudi Arabia and the broader Middle East and North Africa region.
• May 2025: Metropolis Healthcare launched TruHealth Cancer Screen 360 in India, comprising male and female cancer-screening profiles with complimentary genetic counseling to improve access to preventive oncology screening and personalized cancer-risk assessment.
• March 2025: My Gene Counsel and FamGenix entered into a strategic partnership to integrate digital genetic counseling education with family-health-history and hereditary-risk assessment capabilities.
• January 2025: MyOme and Novi Health announced a collaboration to provide whole-genome sequencing and genetic counseling services through employer health programs.

REPORT COVERAGE

The global genetic counseling market analysis includes a comprehensive study of the market size & forecast by all the market segments included in the report. It includes details on the market dynamics and market trends expected to drive the market over the forecast period. It provides information on key aspects, including an overview of technological advancements, the regulatory environment, and product launches. Additionally, it details partnerships, mergers & acquisitions, as well as key industry developments and investments by key regions. The global market research report also provides a deep competitive landscape with information on the market share and profiles of key operating players.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1. Country-Level Genetic Counseling Utilization & Spending Analysis

• Assess genetic counseling utilization across each country in scope, covering reproductive genetics, oncology genetics, pediatric & rare disease genetics, cardiovascular & neurogenetics, predictive & pharmacogenomic genetics, and other qualifying applications.
• Analyze the number of practicing genetic counselors, patient referral volumes, genetic testing activity, hospital genetics programs, specialist clinics, and access to counseling services.
• Separate genetic counseling expenditure from broader genetic testing, sequencing, laboratory diagnostics, medical genetics consultations, and genomics-related healthcare expenditure.
• Evaluate country-level reimbursement, insurance coverage, self-pay utilization, public healthcare funding, consultation pricing, genetic counselor availability, and healthcare/genomics infrastructure.
• Assess counseling penetration across pre-test, post-test, integrated, and follow-up & family counseling services.
• Estimate country market values using counseling encounters × counseling penetration × average revenue/reimbursement per encounter, and aggregate country estimates into regional and global totals.

Approach 2: Bottom-Up Counselor Capacity & Service Volume Analysis

• Estimate the number of practicing genetic counselors across each country and adjust for counselors engaged primarily in non-clinical roles.
• Allocate counselors across Hospitals & Academic Centers, Genetic Counseling Clinics, and Others.
• Estimate annual counseling encounters per counselor based on working days, consultations per day, part-time/full-time mix, and clinical utilization.
• Estimate utilization separately across adults and pediatric populations and across the major application segments.
• Apply country-specific average consultation fees, reimbursement rates, institutional payments, and self-pay pricing.
• Calculate market value using active clinical counselors × annual counseling encounters per counselor × average attributable revenue per encounter, with adjustments for unpaid, bundled, or laboratory-sponsored counseling to prevent overestimation.

Approach 3: Credible Secondary Sources & Institutional Data Cross-Check

• Use NSGC, ABGC, AGNC, CAGC, HGSA, ESHG, ACMG, and relevant national genetics organizations for counselor workforce, professional practice, certification, service-delivery patterns, and genetics-care standards.
• Use CDC, NIH/NHGRI, CMS, NHS, MHLW, national health ministries, reimbursement authorities, and national genomics programs for utilization, reimbursement, healthcare-system, and genetics-service validation.
• Use WHO, OECD, Eurostat, World Bank, national statistical organizations, cancer registries, rare-disease programs, and population-health databases for demographic, disease-burden, healthcare expenditure, and infrastructure validation.
• Validate counselor workforce, genetic testing activity, counseling penetration, referral patterns, consultation volumes, service-provider structure, reimbursement, and adoption of tele-genetic counseling.
• Use official company websites, annual reports, filings, provider statistics, service pricing, contracts, partnership announcements, and program disclosures for commercial validation.
• Exclude third-party syndicated market-research publishers as primary evidence for market size, market shares, growth rates, and country-level estimates.

2. Top Down Approaches

Approach 1:  Revenues and Market Share of Major Players (2021-2025)

• Collect company/provider-level revenues and operating indicators from annual reports, SEC filings, investor presentations, company disclosures, hospital/health-system publications, and service-provider websites.
• Map providers to the finalized Service Type, Application, Age Group, and Service Provider segments.
• Separate identifiable genetic counseling revenue from genetic testing, sequencing, laboratory diagnostics, general telehealth, medical genetics, and broader genomics revenues.
• Assess counselor workforce, reported counseling sessions, customer contracts, patient reach, genetic-testing integration, geographic presence, and service breadth.
• Estimate in-scope genetic counseling revenue for providers without separately disclosed counseling revenue using counselor capacity, consultation volume, service pricing, and attributable service indicators.
• Calculate indicative provider market shares, estimate the fragmented Others pool comprising hospitals, academic centers, independent clinics, and smaller providers, and aggregate provider-level revenues to derive the preliminary supply-side market size.

Approach 2: Triangulation, Validation and Forecast Modeling

• Compare estimates derived from provider revenues, country-level counseling spending, counselor-capacity analysis, genetic testing utilization, and credible institutional sources.
• Investigate and reconcile material differences between supply-side provider estimates and bottom-up demand/utilization estimates.
• Remove genetic testing, sequencing, diagnostic laboratory, physician consultation, generic telehealth, and other non-counseling revenues while preventing double counting of bundled services.
• Validate estimates against counselor workforce, counseling-session volumes, genetic testing volumes, reimbursement levels, provider capacity, referral patterns, population demographics, and healthcare infrastructure.
• Develop country, regional, and segment forecasts using genetic testing growth, hereditary cancer screening, reproductive genetics, rare disease diagnosis, counselor workforce expansion, tele-genetic counseling, reimbursement changes, national genomics programs, and service-price trends.
• Apply conservative, base, and high-growth scenarios and finalize the market size and 2026–2034 CAGR after triangulation across all approaches.

3. List of Key Sources

• Annual reports, SEC/regulatory filings, investor presentations, earnings disclosures, provider statistics, contracts, partnership announcements, and service-level commercial disclosures
• National Society of Genetic Counselors (NSGC)
• American Board of Genetic Counseling (ABGC)
• American College of Medical Genetics and Genomics (ACMG)
• Association of Genetic Nurses and Counsellors (AGNC)
• Canadian Association of Genetic Counsellors (CAGC)
• Human Genetics Society of Australasia (HGSA)
• European Society of Human Genetics (ESHG)
• Country-level genetic counseling and human genetics associations
• U.S. Centers for Disease Control and Prevention (CDC)
• National Institutes of Health / National Human Genome Research Institute (NIH / NHGRI)
• Centers for Medicare & Medicaid Services (CMS)
• U.S. Bureau of Labor Statistics and state genetic counselor licensing authorities
• NHS and other national healthcare authorities
• National genomics and precision-medicine programs
• MHLW / PMDA
• National Health Commission of China / NMPA
• ICMR / CDSCO
• Australian health authorities / AHPRA / TGA
• WHO
• OECD
• Eurostat
• World Bank
• National cancer, rare-disease, birth-defect, and population-health registries
• National health ministries, reimbursement agencies, and statistical organizations
• Hospital and academic genetics program disclosures
• Company genetic counseling service pages, pricing information, counselor-network disclosures, customer programs, collaborations, and press releases

4. Primary Interviews

Supply Side Interviews: 60%

• Key respondents: Genetic counseling service providers, hospital and academic genetics-program executives, independent genetic counseling clinics, virtual genetic counseling providers, genomics and diagnostic companies offering counseling services, genetic counselor network managers, clinical program directors, genetic counselors, commercial executives, reimbursement specialists, payer-contracting professionals, and digital genetics-platform providers.
• Validate genetic counseling revenues, consultation pricing, counselor workforce, annual counseling volumes, patient mix, pre-test/post-test service mix, application mix, payer mix, reimbursement, capacity utilization, geographic coverage, referral channels, hospital contracts, tele-genetic counseling adoption, and competitive positioning.
• Demand Side Interviews: 40%
• Key Respondents: Clinical geneticists, oncologists, OB-GYNs, reproductive medicine specialists, pediatricians, neurologists, cardiologists, primary-care physicians, hospital genetics departments, genetic testing laboratories, patient-navigation teams, healthcare payers, employers/population-health programs, and patients or patient-advocacy representatives where appropriate.
• Validate referral rates, counseling utilization, number of encounters per patient, pre-test versus post-test requirements, application-specific demand, testing-linked counseling penetration, wait times, access constraints, payer coverage, out-of-pocket spending, provider preferences, tele-genetic counseling utilization, and unmet demand.